DocDollars

Averitas Pharma Inc.

NJ · United States · Reporting entity ID 100001386985

Total reported 2019–2025
$6.49M
#624 of 2,960 reporting companies — 0% of all reported industry payments
$3.54M in general payments across 39,987 records, plus $2.95M in research funding across 1,139 records.

How it breaks down

General payments $3,535,521
Research funding $2,951,061

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Averitas Pharma Inc. reported $6.49M to US doctors and teaching hospitals from 2019 to 2025, ranking #624 of 2,960 reporting companies. 45% of that was research funding and 55% general payments such as consulting, speaking, food and travel. 39,987 general payment records and 1,139 research records were filed.

Common questions about Averitas Pharma Inc.

How much has Averitas Pharma Inc. paid US doctors?

Averitas Pharma Inc. reported $6,486,582 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,535,521 in general payments, $2,951,061 in research funding.

How does Averitas Pharma Inc. rank among drug and device companies?

It ranks #624 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Averitas Pharma Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.